Melocalm (Meloxicam)

Meloxicam works by selectively inhibiting the cyclo‑oxygenase‑2 (COX‑2) enzyme, which reduces the production of prostaglandins—chemical mediators that cause inflammation, pain and fever. By targeting COX‑2, it provides anti‑inflammatory and analgesic effects while sparing COX‑1 activity that protects the stomach lining.

The appropriate dose of Melocalm is determined by the prescribing clinician based on the patient’s medical condition, severity of symptoms, age, renal and hepatic function, and other individual factors. Patients should follow the prescriber’s instructions and not alter the dose without medical advice.

The safety of meloxicam in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Melocalm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Melocalm (meloxicam) offers relatively selective COX‑2 inhibition, which may lower the risk of gastrointestinal irritation compared with non‑selective NSAIDs like ibuprofen or naproxen. However, it still carries cardiovascular and renal risks similar to other NSAIDs, and the choice of therapy should be individualized based on patient risk factors.

Melocalm tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Do not store in bathrooms or near heat sources. Keep out of reach of children.

Melocalm is taken orally, usually with a full glass of water. It may be taken with or without food, but taking it with food can help reduce stomach upset. Swallow the tablet whole; do not crush, chew, or split unless instructed by a healthcare professional.

Serious risks include gastrointestinal ulceration or bleeding, cardiovascular events such as heart attack or stroke, renal impairment leading to reduced kidney function, severe liver injury, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they notice signs of these conditions.

Melocalm should be avoided in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal ulceration or bleeding, severe heart failure, uncontrolled hypertension, and in patients with severe renal or hepatic impairment unless specifically directed by a physician.